Formyl-peptide receptors revisited

Trends in Immunology

Volumn 23, Issue 11, 2002, Pages 541-548

  Le, Yingying ^a   Murphy, Philip M ^b   Wang, Ji Ming ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOATTRACTANT; CHEMOTACTIC FACTOR; ENVELOPE PROTEIN; FORMYLPEPTIDE RECEPTOR; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 8; ISOPROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE DERIVATIVE; RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOIDOSIS; BACTERIAL INFECTION; CELL DAMAGE; CELLULAR IMMUNITY; HOST CELL; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LEUKOCYTE; NONHUMAN; PATHOGENESIS; PRION DISEASE; PROTEIN FAMILY; PROTEIN INTERACTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL;

AMYLOIDOSIS; ANIMALS; HUMANS; INFECTION; INFLAMMATION; LIGANDS; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, IMMUNOLOGIC; RECEPTORS, LIPOXIN; RECEPTORS, PEPTIDE; SIGNAL TRANSDUCTION;

EID: 0036839229     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(02)02316-5     Document Type: Review

References (64)

1. Schiffmann E., et al. N-formylmethionyl peptides as chemoattractants for leucocytes. Proc. Natl. Acad. Sci. U. S. A. 72:1975;1059-1062.
2. Schiffmann E., et al. The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli. J. Immunol. 114:1975;1831-1837.
3. Marasco W.A., et al. Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. J. Biol. Chem. 259:1984;5430-5439.
4. Carp H. Mitochondrial N-formylmethionyl proteins as chemoattractants for neutrophils. J. Exp. Med. 155:1982;264-275.
5. Panaro M.A., Mitolo V. Cellular responses to FMLP challenging: a mini-review. Immunopharmacol. Immunotoxicol. 21:1999;397-419.
6. Murphy P.M. The N-formyl-peptide chemotactic receptors. Horuk R., Chemoattractant Ligands and their Receptors. 1996;269-299 CRC Press, Inc, Boca Raton.
7. Prossnitz E.R., Ye R.D. The N-formyl-peptide receptor: a model for the study of chemoattractant receptor structure and function. Pharmacol. Ther. 74:1997;73-102.
8. Le Y., et al. Pleiotropic roles of formyl-peptide receptors. Cytokine Growth Factor Rev. 12:2001;91-105.
9. Gao J.L., et al. Impaired antibacterial host defense in mice lacking the N-formyl-peptide receptor. J. Exp. Med. 189:1999;657-662.
10. Le Y., et al. Receptors for chemotactic formyl peptides as pharmacological targets. Int. Immunopharmacol. 2:2002;1-13.
11. Liang T.S., et al. The endogenous opioid spinorphin blocks fMet-Leu-Phe-induced neutrophil chemotaxis by acting as a specific antagonist at the N-formyl-peptide receptor subtype FPR. J. Immunol. 167:2001;6609-6614.
12. Boulay F., et al. synthesis and use of a novel N-formyl-peptide derivative to isolate a human N-formyl peptide receptor cDNA. Biochem. Biophys. Res. Commun. 168:1990;1103-1109.
13. Boulay F., et al. The human N-formyl-peptide receptor. Characterization of two cDNA isolates and evidence for a new subfamily of G-protein-coupled receptors. Biochemistry. 29:1990;11123-11133.
14. Ye R.D., et al. Isolation of a cDNA that encodes a novel granulocyte N-formyl-peptide receptor. Biochem. Biophys. Res. Commun. 184:1992;582-589.
15. Murphy P.M., et al. A structural homologue of the N-formyl-peptide receptor. Characterization and chromosome mapping of a peptide chemoattractant receptor family. J. Biol. Chem. 267:1992;7637-7643.
16. Bao L., et al. Mapping of genes for the human C5a receptor (C5AR), human FMLP receptor (FPR) and two FMLP receptor homologue orphan receptors (FPRH1, FPRH2) to chromosome 19. Genomics. 13:1992;437-440.
17. Durstin M., et al. Differential expression of members of the N-formyl-peptide receptor gene cluster in human phagocytes. Biochem. Biophys. Res. Commun. 201:1994;174-179.
18. Christophe T., et al. The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2. J. Biol. Chem. 276:2001;21585-21593.
19. Betten A., et al. A proinflammatory peptide from Helicobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosis. J. Clin. Invest. 108:2001;1221-1228.
20. Yang, D. et al. Human dendritic cells express functional formyl-peptide receptor-like2 (FPRL2) throughout maturation J. Leukoc. biol. (in press)
21. Yang D., et al. Differential regulation of formyl-peptide receptor-like 1 expression during the differentiation of monocytes to dendritic cells and macrophages. J. Immunol. 166:2001;4092-4098.
22. Braun M.C., et al. Activation of the formyl-peptide receptor by the HIV-derived peptide T-20 suppresses interleukin-12 p70 production by human monocytes. Blood. 97:2001;3531-3536.
23. Gao J.L., et al. Differential expansion of the N-formyl-peptide receptor gene cluster in human and mouse. Genomics. 51:1998;270-276.
24. Hartt J.K., et al. N-formyl peptides induce two distinct concentration optima for mouse neutrophil chemotaxis by differential interaction with two N-formyl-peptide receptor (FPR) subtypes: molecular characterization of FPR2, a second mouse neutrophil FPR. J. Exp. Med. 190:1999;741-747.
25. Takano T., et al. Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J. Exp. Med. 185:1997;1693-1704.
26. Sahagun-Ruiz A., et al. Contrasting evolution of the human leukocyte N-formyl-peptide receptor subtypes FPR and FPRL1R. Genes Immun. 2:2001;335-342.
27. Partida-Sanchez S., et al. Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nat. Med. 7:2001;1209-1216.
28. Gwinn M.R., et al. Single nucleotide polymorphisms of the N-formyl-peptide receptor in localized juvenile periodontitis. J. Periodontol. 70:1999;1194-1201.
29. Seifert R., Wenzel-Seifert K. Defective Gi protein coupling in two formyl-peptide receptor mutants associated with localized juvenile periodontitis. J. Biol. Chem. 276:2001;42043-42049.
30. Van Dyke T.E., et al. Reduced chemotactic peptide binding in juvenile periodontitis: a model for neutrophil function. Biochem. Biophys. Res. Commun. 100:1981;1278-1284.
31. Daniel M.A., et al. Defective chemotaxis and calcium response in localized juvenile periodontitis neutrophils. J. Periodontol. 64:1993;617-621.
32. Yang D., et al. ll-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (fprl1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and t cells. J. Exp. Med. 192:2000;1069-1074.
33. Wild C.T., et al. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U. S. A. 91:1994;9770-9774.
34. Kilby J.M., et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1998;1302-1307.
35. Walther A., et al. A novel ligand of the formyl-peptide receptor: annexin I regulates neutrophil extravasation by interacting with the FPR. Mol. Cell. 5:2000;831-840.
36. Perretti M., et al. Mobilizing lipocortin 1 in adherent human leukocytes downregulates their transmigration. Nat. Med. 2:1996;1259-1262.
37. Yang Y., et al. Inhibitory effect of annexin I on synovial inflammation in rat adjuvant arthritis. Arthritis Rheum. 42:1999;1538-1544.
38. D'Amico M., et al. Lipocortin 1 reduces myocardial ischemia-reperfusion injury by affecting local leukocyte recruitment. FASEB J. 14:2000;1867-1869.
39. Perretti M., et al. Involvement of the receptor for formylated peptides in the in vivo anti-migratory actions of annexin 1 and its mimetics. Am. J. Pathol. 158:2001;1969-1973.
40. Rescher U., et al. Functional activation of the formyl-peptide receptor by a new endogenous ligand in human lung A549 cells. J. Immunol. 169:2002;1500-1504.
41. Fiore S., et al. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J. Exp. Med. 180:1994;253-260.
42. Serhan C.N. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity? Prostaglandins. 53:1997;107-137.
43. Chiang N., et al. Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. J. Exp. Med. 191:2000;1197-1208.
44. Maddox J.F., Serhan C.N. Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J. Exp. Med. 183:1996;137-146.
45. Hachicha M., et al. Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1α-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J. Exp. Med. 189:1999;1923-1930.
46. Maderna P., et al. Lipoxins induce actin reorganization in monocytes and macrophages but not in neutrophils: differential involvement of rho GTPases. Am. J. Pathol. 160:2002;2275-2283.
47. Gronert K., et al. Selectivity of recombinant human leukotriene D(4), leukotriene B(4) and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. Am. J. Pathol. 158:2001;3-9.
48. Aliberti J., et al. Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nat. Immunol. 3:2002;76-82.
49. Dano K., et al. Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. APMIS. 107:1999;120-127.
50. Boyle M.D., et al. Urokinase: a chemotactic factor for polymorphonuclear leukocytes in vivo. J. Immunol. 139:1987;169-174.
51. Resnati M., et al. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc. Natl. Acad. Sci. U. S. A. 99:2002;1359-1364.
52. Su S.B., et al. A seven-transmembrane, G-protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J. Exp. Med. 189:1999;395-402.
53. 42 activates a G protein-coupled chemoattractant receptor FPR-like 1. J. Neurosci. 21:2000;1-5.
54. Le Y., et al. The neurotoxic prion peptide fragment PrP(106-126) is a chemotactic agonist for the G protein-coupled receptor formyl-peptide receptor-like 1. J. Immunol. 166:2001;1448-1451.
55. Stone M.J. Amyloidosis: a final common pathway for protein deposition in tissues. Blood. 75:1990;531-545.
56. Neuroinflammatory Working Group . Inflammation and Alzheimer's disease. Neurobiol. Aging. 21:2000;383-421.
57. Mackenzie I.R., Munoz D.G. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology. 50:1998;986-990.
58. Tiffany H.L., et al. Amyloid-β induces chemotaxis and oxidant stress by acting at formylpeptide receptor 2, a G protein-coupled receptor expressed in phagocytes and brain. J. Biol. Chem. 276:2001;23645-23652.
59. Cui Y.H., et al. Bacterial lipopolysaccharide selectively upregulates the function of the chemotactic peptide receptor formyl-peptide receptor 2 in murine microglial cells. J. Immunol. 168:2002;434-442.
60. Yazawa H., et al. β amyloid peptide (Aβ42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages. FASEB J. 15:2001;2454-2462.
61. Brown D.R., Kretzschmar H.A. Microglia and prion disease: a review. Histol. Histopathol. 12:1997;883-892.
62. McCoy R., et al. N-formylpeptide and complement C5a receptors are expressed in liver cells and mediate hepatic acute phase gene regulation. J. Exp. Med. 182:1995;207-217.
63. Le Y., et al. Expression of functional formyl-peptide receptors by human astrocytoma cell lines. J. Neuroimmunol. 111:2000;102-108.
64. Keitoku M., et al. FMLP actions and its binding sites in isolated human coronary arteries. J. Mol. Cell. Cardiol. 29:1997;881-894.